Brief: Soligenix Achieves Important Safety Milestone In Its Confirmatory Phase 3 Clinical Trial Of Hybryte™ For The Treatment Of Cutaneous T-Cell Lymphoma
07/10/2025 12:56
Oct 7 (Reuters) - Soligenix Inc SNGX.O: SOLIGENIX ACHIEVES IMPORTANT SAFETY MILESTONE IN ITS CONFIRMATORY PHASE 3 CLINICAL TRIAL OF HYBRYTE™ FOR THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA SOLIGENIX INC - FLASH2 STUDY INTERIM EFFICACY ANALYSIS TARGETED FOR 1H2026 SOLIGENIX INC - ENROLLMENT UPDATE REMAINS ON TRACK FOR 4Q2025 Source text: ID:nPn9w68WTa Further company coverage: SNGX.O ((Reuters.Briefs@thomsonreuters.com;))